Fidelity Investments
SCPS

Fidelity Investments’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Fidelity Investments’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed – – 5158
2021
Q3 		$0 Buy
+100
New +$515 ﹤0.01% 5278

Other funds holding SCPS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments's SCPS Position: Q4 2021 in Review

Fidelity Investments sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2021, closing a stake of 100 shares.

Fidelity Investments first reported a position in SCPS in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 21 funds tracked by Wall St. Rank hold SCPS as of Q4 2021.

  • Fidelity Investments reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Fidelity Investments sold 100 Scopus BioPharma Inc. Common Stock shares in Q4 2021.
  • Fidelity Investments first reported a position in Scopus BioPharma Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Fidelity Investments's Scopus BioPharma Inc. Common Stock position peaked at $0 in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2021.

Based on Fidelity Investments's 13F filing for Q4 2021, filed 14 Feb 2022.